BENTSUR RON — SEC Form 4 filings
SEC reporting owner CIK 1251213. 11 Form 4 filings on record with FilingPulse; latest filed 2026-07-01.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-03-19 to 2026-07-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 7 legs across 7 filings — 50,940 shares, $475,251 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: purchase of 12,500 shares @ $20.00 ($250,000) in Nuvectis Pharma, Inc., filed 2026-07-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | Chairman & CEO, Director, 10% owner | 9 | 7 legs · 50,940 sh · $475,251 | — | 2 |
| Beyond Air, Inc. (XAIR) | Director | 2 | — | — | 13 |
Form 4 filings — BENTSUR RON
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 12,500 @ $20 | EDGAR |
| 2026-01-09 | 4 | Nuvectis Pharma, Inc. (NVCT) | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-11-06 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 5,000 @ $5.72 | EDGAR |
| 2025-01-03 | 4 | Nuvectis Pharma, Inc. (NVCT) | Grant/award (A): 250,000 @ $0 | EDGAR |
| 2024-12-26 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 4,500 @ $4.65 | EDGAR |
| 2024-11-26 | 4 | Beyond Air, Inc. (XAIR) | Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Grant/award (A): 40,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Grant/award (A): 30,000 (derivative) · +6 more | EDGAR |
| 2024-11-18 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 20,000 @ $4.92 | EDGAR |
| 2024-05-15 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 1,940 @ $6.74 | EDGAR |
| 2024-05-13 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 2,000 @ $6.40 | EDGAR |
| 2024-03-21 | 4 | Beyond Air, Inc. (XAIR) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Nuvectis Pharma, Inc. (NVCT) | Purchase (P): 5,000 @ $10.29 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1251213 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →